George, D. J., Ramaswamy, K., Yang, H., Liu, Q., Zhang, A., Greatsinger, A., … Freedland, S. J. (2025). Plain language summary: how long do patients with metastatic castration-resistant prostate cancer (mCRPC) live when taking abiraterone or enzalutamide in the real world? Future Oncol, 21(11), 1297–1306. https://doi.org/10.1080/14796694.2025.2485752

George, Daniel J., Krishnan Ramaswamy, Hongbo Yang, Qing Liu, Adina Zhang, Alexandra Greatsinger, Jasmina Ivanova, et al. “Plain language summary: how long do patients with metastatic castration-resistant prostate cancer (mCRPC) live when taking abiraterone or enzalutamide in the real world?” Future Oncol 21, no. 11 (May 2025): 1297–1306. https://doi.org/10.1080/14796694.2025.2485752.

George DJ, Ramaswamy K, Yang H, Liu Q, Zhang A, Greatsinger A, et al. Plain language summary: how long do patients with metastatic castration-resistant prostate cancer (mCRPC) live when taking abiraterone or enzalutamide in the real world? Future Oncol. 2025 May;21(11):1297–306.

George, Daniel J., et al. “Plain language summary: how long do patients with metastatic castration-resistant prostate cancer (mCRPC) live when taking abiraterone or enzalutamide in the real world?” Future Oncol, vol. 21, no. 11, May 2025, pp. 1297–306. Pubmed, doi:10.1080/14796694.2025.2485752.

George DJ, Ramaswamy K, Yang H, Liu Q, Zhang A, Greatsinger A, Ivanova J, Thompson B, Emir B, Hong A, Freedland SJ. Plain language summary: how long do patients with metastatic castration-resistant prostate cancer (mCRPC) live when taking abiraterone or enzalutamide in the real world? Future Oncol. 2025 May;21(11):1297–1306.